Business context and reporting period
Entity note: Although the request metadata identifies SELLAS Life Sciences Group, Inc., the supplied filing is Galena Biopharma, Inc.’s Form 10-K. It covers the fiscal year ended December 31, 2014; quarterly figures below refer to Q4 2014.
Galena developed oncology therapies and marketed Abstral (fentanyl) for breakthrough cancer pain. It licensed U.S. commercial rights to Zuplenz (ondansetron) in 2014, but had not recorded Zuplenz revenue by year-end. Its principal development programs were NeuVax, in a Phase 3 breast-cancer recurrence-prevention trial; GALE-301, in Phase 2a; and GALE-401, in Phase 2.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Net revenue | $9.3 million | $2.5 million |
| Operating loss | $52.2 million | $33.8 million |
| Net loss | $36.6 million | $76.7 million |
| Net loss per share | $0.31 | $0.85 |
| Net cash used in operating activities | $42.9 million | $28.9 million |
- Revenue was from Abstral. Gross revenue rose 114%, while net revenue increased 275%, reflecting a full year of sales versus a partial year in 2013 and lower gross-to-net deductions. Those deductions were 43% of gross revenue for 2014, versus 67% in 2013.
- Gross profit, after cost of revenue and acquired-intangible amortization, was approximately $7.5 million, or about 80% of net revenue. The filing reports gross profit of $2.5 million for Q4 2014, compared with $1.0 million in Q4 2013.
- R&D expense rose 35% to $28.4 million, mainly due to the Phase 3 PRESENT trial. SG&A rose 115% to $31.3 million, including approximately $7 million in litigation-related legal expenses, partly offset by $2 million in insurance recoveries.
- The smaller 2014 net loss versus 2013 did not reflect improved operating performance: operating loss increased. Non-operating income included a $60.6 million reduction in the fair value of warrant liabilities, primarily associated with the falling share price.
- Cash and cash equivalents were $23.7 million at year-end, down from $47.8 million. Total assets were $80.5 million; total debt on the balance sheet was $8.4 million, including $3.9 million current and $4.5 million long-term. The contractual debt schedule includes principal and interest and reports $9.5 million total obligations.
- Cash used in investing activities was $5.5 million; financing activities provided $24.3 million, including equity issuance and option and warrant exercises. As of February 28, 2015, cash and cash equivalents were approximately $21.3 million.
Material changes versus the prior comparable period
- Annual net revenue increased by $6.8 million, with Abstral’s strongest prescription quarter occurring in Q4. Q4 net revenue was $3.2 million versus $1.3 million in Q4 2013.
- Operating expenses expanded with commercial staffing and clinical development. The company acquired GALE-401 rights and licensed Zuplenz U.S. rights during 2014.
- Year-end cash declined by $24.1 million. Operating cash use increased by $13.9 million year over year.
- At year-end, the fair value of warrant liabilities was $5.4 million, compared with $49.0 million in 2013, contributing substantially to the swing in reported non-operating results.
Outlook, risks, contingencies, and unusual items
- Management expected 2015 net revenue from commercial products of approximately $15 million to $18 million, with Zuplenz launch anticipated in Q2 2015. The company expected gross-to-net deductions to remain around 30%–35%. These are forecasts, not assurances.
- Management stated that cash, available equity facilities, and Abstral revenue were expected to fund operations for at least one year. The company also expected continued operating losses and stated that it might need further financing; additional equity could dilute shareholders.
- NeuVax Phase 3 enrollment reached the protocol target of 700 patients in February 2015; final enrollment was expected near the end of Q1 2015. Management expected GALE-301 Phase 2a top-line data and GALE-401 Phase 2 data during 2015. Preliminary GALE-301 results showed a 38% relative-risk reduction in recurrence, but were not final results.
- Risks include clinical-trial failure or delay, regulatory approval uncertainty, dependence on external manufacturers and suppliers, reimbursement and commercial uptake, and intense generic and branded competition. The Phase 3 trial had significant site and patient exposure in Russia and Ukraine, where political instability could disrupt trial activity.
- Galena received an FDA Form 483 after a November 2014 inspection, with observations concerning quality-unit procedures and adverse-event reporting. Management said it had identified and was addressing the issues. The filing does not report a final regulatory resolution.
- Actavis challenged Orexo’s listed patents covering Abstral and sought to market a generic. Galena said it was responsible for 88% of related patent-defense legal costs.
- Shareholder derivative and securities class-action litigation remained pending, and the SEC was investigating certain use of outside investor-relations professionals. No liability was recorded for the claims at year-end; insurance coverage was subject to insurers’ reservations of rights. The Delaware derivative action was dismissed without prejudice in February 2015.
- The company had contingent value rights tied to NeuVax milestones, with up to $30 million of potential remaining consideration; payment could be made in cash or stock. Auditors issued unqualified opinions on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Confirm the issuer: the supplied 10-K is for Galena Biopharma, not SELLAS Life Sciences Group.
- Track actual 2015 commercial revenue, Zuplenz launch and uptake, and whether gross-to-net deductions met management’s expectations.
- Review cash burn, financing-facility availability, debt service, and any additional equity issuance or resulting dilution.
- Verify NeuVax, GALE-301, and GALE-401 trial enrollment, results, timelines, and regulatory progress against subsequent disclosures.
- Monitor the FDA’s response to the Form 483 corrective actions, Abstral patent litigation, shareholder claims, and the SEC investigation.